| DB ID | MyCo_5656 |
| Title | Role of biomarkers in the diagnosis of invasive aspergillosis in immunocompromised patients |
| Year | 2022 |
| PMID | 36320074 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | HIV-AIDS |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The ethics committee of the national institute for medical research develop- ment institute approved this study (IR.NIMAD.REC.1397.155). It was carried out as per the Declaration of Helsinki. Sampling was done as a part of the diagnosis process. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | WBC |
| Biomarker Full Name | white blood cells count |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Iran |
| Cohort | From June 2018 to June 2020, immunocompromised patients with suspected probable/proven IA were admit- ted to Shiraz University Hospitals, southern Iran enrolled in this study. One hundred ninety sera from 52 immunocompromised patients and volunteers were included in this study (18 immunocompromised volunteers without IA as control and 34 patients with probable and proven IA). |
| Cohort No. | 52 |
| Age Group | None |
| P Value | p< 0.001 |
| Sensitivity | 0.647 |
| Specificity | 1 |
| Positive Predictive Value | 1 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is one of the dominant causes of morbidity and mortality in immunocompromised patients. Infection may be associated with many factors like age, graft-versus-host disease, prolonged neu- tropenia, diabetes, cytomegalovirus infection, post oper- ative infection, renal or liver dysfunction, steroid therapy, and chemotherapy. Preliminary diagnosis and treatment play an important role in the handling of high- risk patients. Optimizing the usage of antifungal agents (antifungal stewardship programs) has an important character in decreasing antifungal toxicity, antifungal resistance, and cost. Conventional diagnostic methods based on culture and histology of sterile clinical samples remain the cornerstone of diagnosis. However, the performance of such methods in immunocompromised patients may be underlying co-morbidities. Non-cul- ture-based methods such as 1,3-b-D glucan, galactoman- nan, and DNA assay are reliable ones for early diagnosis of IA by the detection of Aspergillus antigen components. Although the mortality rate for aspergillosis has been declining from 60 to 70% to around 40%, new labo- ratory methods that impart correct and rapid results are required for the diagnosis of this infection. |
| Technique | PCR |
| Analysis Method | qRT-PCR |
| ELISA kits | ELISA Kits (Shanghaicrystal Day Biotech co. LTD, China). |
| Assay Data | None |
| Validation Techniques used | ELISA, qRT-PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
